Adastra Pharmaceuticals Announces Positive Interim Data from Phase 1b Clinical Trial of Zotiraciclib in the Treatment of Recurrent Malignant Gliomas

National Cancer Institute (NCI) Study Designed to Investigate Zotiraciclib in Combination with Temozolomide (TMZ) Presented During Poster Session at ASCO 2019 Maximum Tolerated Dose of Zotiraciclib (250mg) Elicits Tumor Reduction, Suggesting Activity in Glioblastoma...
SEARCH FOR STUDIES